L. P. Swift

发表

SNM1A (DCLRE1A) is required for the efficient repair of complex DNA breaks in human cells

P. McHugh, C. Schofield, B. Lagerholm, 2022, bioRxiv.

Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species

A. Nudelman, S. Cutts, A. Rephaeli, 2008, Cancer Chemotherapy and Pharmacology.

Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.

O. Gileadi, P. McHugh, N. Burgess-Brown, 2011, Genes & development.

Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.

A. Nudelman, S. Cutts, A. Rephaeli, 2006, Cancer research.

Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate

A. Nudelman, S. Cutts, A. Rephaeli, 2007, Molecular Cancer Therapeutics.

Barminomycin, a model for the development of new anthracyclines.

K. Kimura, R. Brownlee, S. Cutts, 2010, Anti-cancer agents in medicinal chemistry.

Sequence specificity of adriamycin-DNA adducts in human tumor cells.

A. Nudelman, S. Cutts, A. Rephaeli, 2003, Molecular cancer therapeutics.

Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.

Abraham Nudelman, Ada Rephaeli, A. Nudelman, 2003, Molecular cancer therapeutics.

Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.

A. Nudelman, S. Cutts, A. Rephaeli, 2012, Biochemical pharmacology.

The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity

A. Nudelman, S. Cutts, A. Rephaeli, 2008, Cancer Chemotherapy and Pharmacology.

Characterization of the SARS-CoV-2 ExoN (nsp14ExoN–nsp10) complex: implications for its role in viral genome stability and inhibitor identification

G. Morris, O. Gileadi, P. McHugh, 2020, bioRxiv.

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection

P. McHugh, Ricky A. Sharma, S. Caporali, 2013, International journal of cancer.

The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts

A. Nudelman, S. Cutts, A. Rephaeli, 2013, Cancer Chemotherapy and Pharmacology.

SNM1A (DCLRE1A) is crucial for efficient repair of complex DNA breaks in human cells

P. McHugh, J. Newman, C. Schofield, 2023, bioRxiv.

Cell-active small molecule inhibitors validate the SNM1A DNA repair nuclease as a cancer target

Philip S. Jones, O. Gileadi, P. McHugh, 2024, Chemical Science.